Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03017729 · ClinicalTrials.gov registry record
Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 242
- Enrollment target
NCT03017729 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 242 participants.
The verdict
NCT03017729 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the longitudinal attainment of subject centred and functional related goals (cumulated Goal Attainment Scale Total (GAS T) score) after abobotulinumtoxinA injection (including following repeated injection cycles where they occur) alongside spasticity management used in real life settings over a period of 18 months (and a maximum of six injection cycles).
Interventions
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2017-02-10 |
| Est. Completion | 2020-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03017729
The ClinicalTrials.gov registry entry for NCT03017729 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.
NCT03017729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03017729 about?
NCT03017729 is a clinical study titled "Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity". The purpose of this study is to assess the longitudinal attainment of subject centred and functional related goals (cumulated Goal Attainment Scale Total (GAS T) score) after abobotulinumtoxinA injection (including following repeated injection cycles where they occur) alongside spasticity management...
What is the current status of trial NCT03017729?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2017-02-10. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT03017729?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03017729?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.